Jiangsu Aosaikang Pharmaceutical Co., Ltd. clinical trials
A subsidiary of Beijing Aosaikang Pharmaceutical Co., Ltd.
The registry lists 14 studies whose lead sponsor is Jiangsu Aosaikang Pharmaceutical Co., Ltd.. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 27, 2026.
- 14studies on the registry
- 6open to participants now
- 3phase 3 studies under way
- 3reach primary completion within a year
What it is testing
The drugs Jiangsu Aosaikang Pharmaceutical Co., Ltd.’s studies test, most open studies first — 7 drugs with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
Coming up
3 of Jiangsu Aosaikang Pharmaceutical Co., Ltd.’s studies under way reach primary completion within a year, 1 of them phase 3. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- 1DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- 2OOct
- NNov
All 3
- Dec 2026Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067ASKC202 · NCT05306132
- Oct 2027ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI TherapyASKC202, ASK-120067 · Phase 3 · NCT07109531
- Oct 2027ASK0912 Versus Polymyxin B for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial PneumoniaNCT07759934
Add all 3 to your calendar (.ics) → With an account.
What changed recently
From the registry's own updates since Oct 17, 2026.
Newly registered1
All 14 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 326
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.14 studies
Something wrong with this grouping? Tell us on the Beijing Aosaikang Pharmaceutical Co., Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 14 of 14. All Beijing Aosaikang Pharmaceutical Co., Ltd. studies →
- ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLCNot yet recruitingNCT07897188Phase 3
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS MutationsNot yet recruitingNCT07836036Phase 1
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI TherapyRecruitingNCT07109531Phase 3
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- ASK0912 Versus Polymyxin B for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial PneumoniaRecruitingNCT07759934Phase 2
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067RecruitingNCT05306132Phase 1
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- The Safety and Pharmacokinetics of ASKC200 in Osteoarthritic Knee PainNot yet recruitingNCT06614608Phase 1
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- ASKC200 for Knee Osteoarthritis PainActive, not recruitingNCT07742852Phase 2
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Safety and Efficacy Study of Ferric Maltol To Treat Iron Deficiency Anaemia in Chinese Patients With Inflammatory Bowel DiseaseCompletedNCT07739368Phase 3
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT04632108Phase 1/2
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLCActive, not recruitingNCT04143607Phase 3
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or ItraconazoleCompletedNCT05631678Phase 1
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung CancerStatus unknownNCT03502850Phase 1/2
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy SubjectsCompletedNCT04360915Phase 1
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Pharmacokinetics and Safety Study of ASKB1202 in Chinese Healthy SubjectsStatus unknownNCT03115762Phase 1
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.